Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Journal of Investigative Dermatology

Volumn 135, Issue 11, 2015, Pages 2632-2640

  Warren, Richard B ^a   Smith, Catherine H ^b   Yiu, Zenas Z N ^a   Ashcroft, Darren M ^c   Barker, Jonathan N W N ^b   Burden, A David ^d   Lunt, Mark ^a   McElhone, Kathleen ^a   Ormerod, Anthony D ^e   Owen, Caroline M ^f   Reynolds, Nick J ^g   Griffiths, Christopher E M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d WESTERN INFIRMARY   (United Kingdom)

^e UNIVERSITY OF ABERDEEN   (United Kingdom)

^f ROYAL BLACKBURN HOSPITAL   (United Kingdom)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLOSPORIN A; ETANERCEPT; INFLIXIMAB; METHOTREXATE; USTEKINUMAB; BIOLOGICAL PRODUCT;

ADULT; ARTICLE; BIOLOGICAL THERAPY; BODY MASS; BREAST DISEASE; CLINICAL DECISION MAKING; COHORT ANALYSIS; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; DISEASE DURATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR DISEASE; ENDOCRINE DISEASE; EYE DISEASE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GENITAL TRACT INFECTION; HEART DISEASE; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HUMAN; IMMUNE DEFICIENCY; IMMUNOPATHOLOGY; INFECTION; INNER EAR DISEASE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; MIDDLE AGED; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; OBSERVATIONAL STUDY; ONSET AGE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RESPIRATORY TRACT DISEASE; RISK FACTOR; SENSITIVITY ANALYSIS; SKIN DISEASE; TREATMENT DURATION; VASCULAR DISEASE; COMPARATIVE STUDY; DERMATOLOGY; DOSE RESPONSE; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MAXIMUM TOLERATED DOSE; MEDICAL SOCIETY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REGISTER;

ADALIMUMAB; ADULT; BIOLOGICAL PRODUCTS; BIOLOGICAL THERAPY; COHORT STUDIES; DERMATOLOGY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ETANERCEPT; FEMALE; HUMANS; INFLIXIMAB; KAPLAN-MEIER ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PSORIASIS; REGISTRIES; SOCIETIES, MEDICAL; USTEKINUMAB;

EID: 84947024119     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2015.208     Document Type: Article

References (29)

1. Barnabe C, Homik J, Barr SG et al. (2014) The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy. J Rheumatol 41:1607-13
2. Bluett J, Morgan C, Thurston L et al. (2014) Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology (Oxford) 54:494-9
3. Bousquet C, Lagier G, Lillo-Le Louet A et al. (2005) Appraisal of the MedDRA conceptual structure for describing and grouping adverse drug reactions. Drug Saf 28:19-34
4. Brunasso AM, Puntoni M, Massone C (2012) Drug survival rates of biologic treatments in patients with psoriasis vulgaris. Br J Dermatol 166:447-9
5. Burden AD, Warren RB, Kleyn CE et al. (2012) The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives. Br J Dermatol 166:545-54
6. Carrascosa JM, van Doorn MB, Lahfa M et al. (2014a) Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies. J Eur Acad Dermatol Venereol 28:1424-30
7. Carrascosa JM, Vilavella M, Garcia-Doval I et al. (2014b) Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry. J Eur Acad Dermatol Venereol 28:907-14
8. Couderc M, Gottenberg JE, Mariette X et al. (2014) Influence of gender on response to rituximab in patients with rheumatoid arthritis: results from the Autoimmunity and Rituximab registry. Rheumatology (Oxford) 53: 1788-93
9. Cramer JA, Roy A, Burrell A et al. (2008) Medication compliance and persistence: terminology and definitions. Value Health 11:44-7
10. Davies EC, Green CF, Taylor S et al. (2009) Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One 4: e4439
11. Di Lernia V, Ricci C, Lallas A et al. (2014) Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers: a retrospective study. J Dermatolog Treat 25:73-4
12. Di Lernia V, Tasin L, Pellicano R et al. (2012) Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis. J Dermatolog Treat 23:404-9
13. Edson-Heredia E, Sterling KL, Alatorre CI et al. (2014) Heterogeneity of response to biologic treatment: perspective for psoriasis. J Invest Dermatol 134: 18-23
14. Esposito M, Gisondi P, Cassano N et al. (2013) Survival rate of antitumour necrosis factor-alpha treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol 169:666-72
15. Franconi F, Campesi I (2014) Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women. Br J Pharmacol 171:580-94
16. Garcia-Doval I, Carretero G, Vanaclocha F et al. (2012) Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol 148:463-70
17. Gniadecki R, Bang B, Bryld LE et al. (2014) Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol 172:244-52
18. Gniadecki R, Kragballe K, Dam TN et al. (2011) Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 164:1091-6
19. Griffiths CE, Strober BE, van de Kerkhof P et al. (2010) Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 362:118-28
20. Lecluse LL, Driessen RJ, Spuls PL et al. (2010) Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol 146:127-32
21. Manteuffel M, Williams S, Chen W et al. (2014) Influence of patient sex and gender on medication use, adherence, and prescribing alignment with guidelines. J Womens Health (Larchmt) 23:112-9
22. Menting SP, Sitaram AS, van der Stok HM et al. (2014) Drug survival not significantly different between biologics in patients with psoriasis vulgaris: a single center database analysis. Br J Dermatol 171:875-83
23. Naldi L, Addis A, Chimenti S et al. (2008) Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatology 217:365-73
24. Pirmohamed M, James S, Meakin S et al. (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329: 15-9
25. Saad AA, Ashcroft DM, Watson KD et al. (2009) Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 11:R52
26. Umezawa Y, Nobeyama Y, Hayashi M et al. (2013) Drug survival rates in patients with psoriasis after treatment with biologics. J Dermatol 40: 1008-13
27. van den Reek JM, Tummers M, Zweegers J et al. (2014a) Predictors of adalimumab drug survival in psoriasis differ by reason for discontinuation: long-term results from the Bio-CAPTURE registry. J Eur Acad Dermatol Venereol 29:560-5
28. van den Reek JM, van Lumig PP, Driessen RJ et al. (2014b) Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis. Br J Dermatol 170:415-24
29. van den Reek JM, Zweegers J, Kievit W et al. (2014c) 'Happy' drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network. Br J Dermatol 171: 1189-96